News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Expands LoramycTM Franchise by Signing a South East Asia Deal Worth up to $12M


3/31/2008 12:10:36 PM

Paris, March 31th, 2008 – BioAlliance Pharma SA (Euronext Paris –BIO) today announced that it has entered into an exclusive licensing agreement under which Korea-based Handok Pharmaceuticals will receive commercialization rights in Korea, Taiwan, Singapore and Malaysia. BioAlliance Pharma’s innovative, muco-adhesive antifungal therapy Loramyc™ (miconazole Lauriad®) is already approved in Europe and a Phase III clinical trial has just completed in the United States.

BioAlliance Pharma’s third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in Korea - the remainder being sales milestones (up to $9 million) in the designated territory and double-digit royalties commensurate with the product stage.

Please, find below the English and French press releases, which are also available in PDF by clicking on the links at the end of this email.

Caroline Carmagnol ALIZE RP Tel.: +33 6 64 18 99 59 Hcaroline@alizerp.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES